Contents

Current Drug Targets - CNS & Neurological Disorders, Volume 1 - Number 2

Preface

, 1(2): i

C. A. Tamminga and Joseph T. Coyle


DOI: 10.2174/1568007024606186




Current Status of Antipsychotic Treatment

, 1(2): 123 - 128

Robert R. Conley and Deanna L. Kelly


DOI: 10.2174/1568007024606221




Treatment of Schizophrenia and Comorbid Substance Use Disorder

, 1(2): 129 - 139

Alan I. Green, Melinda S. Salomon, Mark J. Brenner and Kimberly Rawlins


DOI: 10.2174/1568007024606230




Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis

, 1(2): 141 - 147

C. A. Tamminga and A. Carlsson


DOI: 10.2174/1568007024606195




Nicotinic Agonists and Psychosis

, 1(2): 149 - 162

J. K. Simosky, K. E. Stevens and R. Freedman


DOI: 10.2174/1568007024606168




Muscarinic Receptors as a Target for Drugs Treating Schizophrenia

, 1(2): 163 - 181

Frank P. Bymaster, Christian Felder, Saeed Ahmed and David McKinzie


DOI: 10.2174/1568007024606249




Ionotropic Glutamate Receptors as Therapeutic Targets in Schizophrenia

, 1(2): 183 - 189

Joseph T. Coyle, Guochuan Tsai and Donald C. Goff


DOI: 10.2174/1568007024606212




N-Methyl-D-Aspartate Receptor-Coupled GlycineB Receptors in the Pathogenesis and Treatment of Schizophrenia: A Critical Review

, 1(2): 191 - 213

M. J. Millan


DOI: 10.2174/1568007024606258




Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?

, 1(2): 215 - 225

Darryle D. Schoepp and Gerard J. Marek


DOI: 10.2174/1568007024606177




Novel Directions in Antipsychotic Target Identification using Gene Arrays

, 1(2): 227 - 238

Michael G. Palfreyman, Derek J. Hook, Leszek J. Klimczak, Jeffery A. Brockman, David M. Evans and C. Anthony Altar


DOI: 10.2174/1568007024606203




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science